I recently saw a patient who complained of intermittent numbness in her left hand. She was forty-three, an attorney pulling sixty-hour weeks, and two separate doctors had told her it was stress. When she finally came to us, the MRI showed periventricular white matter lesions. Multiple sclerosis. But the more interesting question was not what was happening in her brain. It was what had been happening in her gut for years before the first lesion ever formed.
A study published in May 2025 in the Proceedings of the National Academy of Sciences just gave us the clearest evidence yet that specific gut bacteria can directly trigger MS. The study design is what makes it so persuasive.
81 Identical Twins, One Critical Difference
Researchers at Ludwig Maximilian University of Munich, led by Hartmut Wekerle and Anneli Peters, recruited 81 pairs of monozygotic twins where one sibling had MS and the other did not. Same DNA. Same childhood environment, same household exposures, same early diet. The only variable left was the disease itself.
They compared the gut microbial profiles of each twin pair and identified 51 bacterial taxa that differed in abundance between the MS-affected and the healthy sibling. The majority of overrepresented organisms in the MS twins belonged to the phylum Firmicutes, a pattern other studies had hinted at but never pinned down in a genetically controlled cohort this large.
But the team did not stop at correlation. They went after causation.
From the Ileum to the Mouse Brain
Four of those twin pairs agreed to undergo enteroscopy, direct sampling of bacteria from the ileum, which is the final segment of the small intestine. This matters because most microbiome studies rely on stool samples, which tell you what is passing through the colon but reveal very little about what is colonizing the small intestine, where the immune system's interaction with gut flora is most active.
The researchers then introduced these ileal samples into germ-free transgenic mice engineered to be susceptible to autoimmune encephalomyelitis, the standard animal model for MS. Mice colonized with bacteria from the MS-affected twin developed MS-like paralysis at substantially higher rates than mice receiving bacteria from the healthy twin.
Two specific organisms drove the effect: Eisenbergiella tayi and a strain of Lachnoclostridium, both members of the Lachnospiraceae family. In the diseased mice, one or both of these species would proliferate explosively, sometimes comprising 75% of the entire gut ecosystem while healthy bacterial diversity collapsed around them.
How Two Bacteria Turn the Immune System Against Myelin
The mechanism appears to involve Th17 immune cell activation. E. tayi produces ethanol and succinate, metabolites known to stimulate Th17 proliferation. Excessive Th17 activity drives the immune attack on myelin, the insulating sheath around nerve fibers that MS progressively destroys.
There is also a likely element of molecular mimicry at work. Surface molecules on these bacteria resemble components of the body's own neural tissue closely enough to confuse immune surveillance. The immune system, primed by the gut flora to attack what it perceives as a foreign invader, turns on the very myelin it should be protecting.
The study also found that female mice were more susceptible to disease development than males. This tracks with the well-established clinical observation that MS affects women roughly three times more often than men. The gut-immune-brain axis may be part of the reason for that disparity.
What This Means for How We Approach MS
For decades, MS has been treated as a disease that starts in the brain. The treatment paradigm has been immunosuppression: shut down the immune attack on myelin and manage relapses as they come. That approach has real value, but it is reactive by design. It addresses the fire without asking what lit the match.
This study reframes the question entirely. If specific gut bacteria can initiate the autoimmune cascade that becomes MS, then the gut is not a peripheral player in this disease. It is the upstream trigger. And that means prevention and early intervention might look very different from what conventional neurology currently offers.
Consider what a proper workup could include: microbiome analysis from stool and potentially ileal sampling, inflammatory marker panels including Th17 cell profiles, assessment of intestinal permeability, and targeted nutritional interventions designed to restore microbial balance before the immune system reaches a tipping point. This is exactly the kind of upstream investigation that the Intensive Brain Health Program was built around. We do not wait for lesions on an MRI to start asking why the brain is under attack.
The Gut as a Therapeutic Target
The practical takeaway here is that diet, gut integrity, and microbial composition are not lifestyle extras tacked onto MS care. They are mechanistic variables that this study directly implicates in the disease process.
Anti-inflammatory nutritional protocols that reduce pathogenic Firmicutes overgrowth, support short-chain fatty acid production from beneficial bacteria, and repair the intestinal lining are directly relevant to this pathophysiology. NAD+ supplementation, omega-3 fatty acids, and targeted probiotics all play roles in modulating gut-immune signaling, which is the reason we developed Action Potential Supplements around the principle of giving the brain what it needs by starting where biology actually starts.
Researchers are also exploring precision probiotics and targeted bacteriophage therapy, interventions designed not to carpet-bomb the microbiome with broad-spectrum antibiotics but to selectively suppress pathogenic strains while preserving the rest of the ecosystem. These approaches are still early-stage, but the trajectory is clear: the future of MS treatment will include the gut, not just the brain.
Two Organisms, One Clinical Imperative
Wekerle and his team at LMU Munich have given us something rare in neuroscience: a clean causal link between specific gut organisms and an autoimmune neurological disease, demonstrated in a genetically controlled human cohort of 81 twin pairs and validated in an animal model. The study appeared in Proceedings of the National Academy of Sciences, volume 122, issue 18.
This work reinforces what we see clinically every day at The Neurogenesis Project. Neurological disease does not begin the day a patient walks through the door with symptoms. It starts years earlier, in metabolic and immunological environments that standard neurology rarely examines. The gut is one of those environments, and we now have names for two of the organisms that can turn it against the brain.
If you are experiencing unexplained neurological symptoms, or if MS runs in your family and you want to understand your actual risk profile rather than wait for a diagnosis, request a consultation and find out what an upstream workup actually looks like.